Unique ID issued by UMIN | UMIN000016423 |
---|---|
Receipt number | R000019070 |
Scientific Title | The assessment of efficacy and safety of Irreversible Electroporation(IRE) to treat unresectable locally advanced pancreatic cancer |
Date of disclosure of the study information | 2015/02/02 |
Last modified on | 2019/08/07 17:38:17 |
The assessment of efficacy and safety of Irreversible Electroporation(IRE) to treat unresectable locally advanced pancreatic cancer
IRE to treat unresectable locally advanced pancreatic cancer
The assessment of efficacy and safety of Irreversible Electroporation(IRE) to treat unresectable locally advanced pancreatic cancer
IRE to treat unresectable locally advanced pancreatic cancer
Japan |
Unresectable locally advanced pancreatic cancer
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Malignancy
NO
Effectiveness of IRE for treatment of unresectable locally advanced pancreatic cancer
Safety
Effectiveness of IRE for treatmetn of unresectable locally advanced pancreatic cancer according to local control rate using CT or MRI performed 6 months after treatment
Incidence and kind of adverse events of up to 1 month after treatment
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment | Maneuver |
Irreversible Electroporation (IRE)
20 | years-old | <= |
Not applicable |
Male and Female
1. It does not matter whether the pre-treatment but it is necessary that 4 weeks was passed from the pre- treatment
2. It has been confirmed pathologically is adenocarcinoma or adenosquamous carcinoma
3. Patient of unresectable locally advanced pancreatic cancer (no distant metastasis, impossible reconstruction of PV/SMV obstruction, more than 180 degrees SMA/CeA invasion, Ao invasion)
4. Major organs (heart, lung, kidney, liver, etc.) function are maintained
a Child-Pugh class A or B
b WBC > 2000/L
c Platelet count > 50000/l
d Prothrombin time > 50%
e Cr<3.0mg/dl
f Total bilirubin level < 3mg/dl
g Cardiac function is normal
5. ECOG score 0 or 1
6. Life expectancy of at least 4 weeks
7. Written informed consent
1. distant metastasis,
2. CT or MRI contrast agent allergy,
3. Another organs malignancy,
4. Pregnant women or women of childbearing potential not using an acceptable method of contraception,
5. Uncontrolled infection
6. Heart failure, coronary artery disease or arrhythmia in progress, active implantable devices (eg pacemaker)
7 Patient's disability to stop anticoagulant and anti platelet therapy
8. Attending physician determines that inappropriate
6
1st name | Akihiko |
Middle name | |
Last name | Tsuchida |
Tokyo Medical University
Gastrointestinal and pediatric surgery
160-0023
6-7-1, Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan
03-3342-6111
akihikot@tokyo-med.ac.jp
1st name | Akihiko |
Middle name | |
Last name | Tsuchida |
Tokyo Medical University
Gastrointestinal and pediatric surgery
160-0023
6-7-1, Nishishinjyuku, Shinjyuku-ku, Tokyo, Japan
03-3342-6111
akihikot@tokyo-med.ac.jp
Tokyo Medical University
Tokyo medical university, Gastrointestinal and pediatric surgery, Gastroenterology and Hepatology
Self funding
Tokyo Medical University
6-7-1, Nishishinjyuku, Shinjyuku-ku, Tokyo
0333426111
kazu-k@tokyo-med.ac.jp
NO
東京医科大学病院(東京都)
2015 | Year | 02 | Month | 02 | Day |
Unpublished
Completed
2014 | Year | 05 | Month | 15 | Day |
2014 | Year | 03 | Month | 31 | Day |
2015 | Year | 02 | Month | 03 | Day |
2017 | Year | 06 | Month | 28 | Day |
2015 | Year | 02 | Month | 02 | Day |
2019 | Year | 08 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019070
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |